Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients

[1]  I. Fabregat,et al.  Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis , 2017, Oncotarget.

[2]  M. Kudo,et al.  Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). , 2017 .

[3]  P. Johnson,et al.  Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Samanta,et al.  "Hepatocellular carcinoma: A life-threatening disease". , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  G. Gerken,et al.  Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. , 2016, Journal of hepatology.

[6]  B. Carr,et al.  Platelets, Microenvironment and Hepatocellular Carcinoma , 2016 .

[7]  Hai-rim Shin,et al.  Prevention of infection-related cancers in the WHO Western Pacific Region. , 2016, Japanese journal of clinical oncology.

[8]  T. Tamura,et al.  A phase I study of resminostat in Japanese patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  D. Mann.  Epigenetics in liver disease , 2014, Hepatology.

[11]  B. Carr,et al.  Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines , 2014, BMC Cancer.

[12]  J. Park,et al.  Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma , 2013, BioMed research international.

[13]  M. Kudo,et al.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Parker,et al.  First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[15]  G. Abou-Alfa,et al.  The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? , 2013, The Lancet. Oncology.

[16]  Gurmit Singh,et al.  Mitochondria and Cancer , 2013, BioMed research international.

[17]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. , 2012, European journal of cancer.

[18]  T. Nagayasu,et al.  Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival , 2011, Digestive Diseases and Sciences.

[19]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[20]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[21]  B. Daniele,et al.  Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .

[22]  J. Furuse,et al.  Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma , 2007, Cancer science.

[23]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.